Thursday, September 29, 2022
News
NEWS HOME
»
PRN INDIA
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
  SocialTwist Tell-a-Friend  
   

  • Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer
  • Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall study population and patients whose tumors harbor an ESR1 mutation
  • U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of February 17, 2023

FLORENCE, Italy and NEW YORK, NY, Aug. 11, 2022 /PRNewswire/ -- The Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

The FDA grants Priority Review designation to medicines that it considers have the potential to provide significant improvements over current SOC in the safety and effectiveness of the treatment, diagnosis, or prevention of serious conditions. The FDA granted Fast Track designation for elacestrant in 2018.

"The FDA's acceptance of our NDA with Priority Review marks an important regulatory milestone  for our company," commented Elcin Barker Ergun, Chief Executive Officer of the Menarini Group. "We look forward to working with the FDA during its review of this submission, which addresses a new potential therapeutic option for a major unmet need in the management of patients with advanced or metastatic breast cancer after resistance builds in the earlier lines of the treatment."

The NDA submission was supported by results of the Phase 3 data from the EMERALD study. EMERALD met both of its pre-specified primary endpoints of progression-free survival (PFS) in the overall population and in patients with the ESR1 mutation (mESR1) compared to SOC endocrine monotherapy; the trial's comparator arms were investigators' choice of either fulvestrant or an aromatase inhibitor. The PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population. The clinical trial data showed that elacestrant reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutation. The data also showed a manageable safety profile.

Elacestrant is an investigational compound and is not approved by any regulatory authorities. The Marketing Authorization Application (MAA) has also been submitted to European Medicines Agency (EMA) in July 2022. More information about clinical trials with elacestrant is available at www.clinicaltrials.gov.

The Menarini Group obtained global licensing rights for elacestrant in July 2020 from Radius Health, Inc (NASDAQ: RDUS), who conducted and successfully completed the EMERALD study. Based on the positive phase 3 data, Stemline, with the support of Radius, submitted a New Drug Application (NDA) in June 2022 to the FDA. The Menarini Group is now fully responsible for global registration, commercialization and further development activities for elacestrant. Stemline, headquartered in New York City, will commercialize elacestrant if approved by the FDA. Stemline is focused on bringing transformational oncology treatments to cancer patients, and currently commercializes a novel targeted treatment for patients with blastic plasmacytoid dendritic cell neoplasm in both the United States and Europe.

About Elacestrant (RAD1901) and the EMERALD Phase 3 Study

Elacestrant is an investigational selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once-daily oral treatment in patients with ER+/ HER2- advanced or metastatic breast cancer. In 2018, elacestrant received Fast Track designation from the FDA. Preclinical studies completed prior to EMERALD indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. The study enrolled 477 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator's choice of an approved hormonal agent. The primary endpoint of the study was progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints included evaluation of overall survival (OS), objective response rate (ORR), and duration of response (DOR).

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Radius

Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, neuro- orphan diseases, and oncology. Radius' lead product, TYMLOS ® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.

Logo: https://mma.prnewswire.com/media/1876570/MENARINI_GROUP.jpg

More News by PR Newswire India

2022 Yidan Prize - world's highest accolade in education - awarded to Dr Linda Darling-Hammond and Professor Yongxin Zhu

Casio to Release Mid-Size G-SHOCK

CLIMATE CHANGE AND HEALTH INEQUITY A DEADLY MIX FOR THE MOST VULNERABLE: WORLD HEART FEDERATION

LyondellBasell Postpones Restart of Berre, France Cracker until Next Year

SI GROUP EXPANDS LUBRICANT ADDITIVE PORTFOLIO WITH NEW AMINIC ANTIOXIDANT

KEREN AVIDAR NAMED INX GLOBAL GENERAL COUNSEL

Asian Hall of Fame Announces Induction 2022

ViewSonic Expands its Gaming Monitor Line with the New OMNI Series for Casual Gamers

Fibocom Launches New Generation of 5G Sub-6GHz and mmWave Module FX170(W) Series Based on Snapdragon X65 5G Modem-RF System at MWC Las Vegas 2022

Himalaya Wellness Company Partners with NIMHANS to Launch Project SURAKSHA

Dr. Giovanni De Micheli Honored with 2022 Phil Kaufman Award Presented by ESD Alliance and IEEE CEDA

Dynata's Global Consumer Trends survey: 53% of people are struggling to afford basic needs; 67% have reduced spending to combat inflation

BellSoft Releases Alpaquita Cloud Native Platform for Java Developers

LCOE-centered, 600W+ module drives global PV market with four key competencies

ABILITY DIABETES GLOBAL - A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

Bitget Ranks As The Top Crypto Derivatives Exchange With 0 Trading Fees

CRMNEXT features in Gartner® Magic Quadrant 2022 as 'Visionary' in Sales Force Automation technology

IBIS STYLES ENTERS THE METAVERSE WITH 2022 'OPEN TO CREATORS' VIRTUAL ART GALLERY & CONTEST - FEATURING DIGITAL CREATORS FROM AROUND THE WORLD

Former CEO of Tricentis and renowned testing industry veteran, Sandeep Johri joins LambdaTest's board

Trina Solar Demonstrates Commitment to India, Showcases Cutting Edge N-Type Module at REI Expo 2022

Lifestyle's new festive campaign inspires one to groove in style

ZTE endorses Catalyzing Electrification Accord

FPT Industrial announces the acquisition of a minority stake in Blue Energy Motors

Moonfare Expands Foothold to India opening Digital Private Market Investing Platform to eligible investors

Ideanomics' subsidiary Energica to provide electric motorcycles for the upcoming G20 Bali summit

DBS Bank India collaborates with HDFC ERGO and Atradius to provide Trade Credit Insurance solution to Tata Metaliks

AFFINIS helps organizations ease compliance with the Structured Digital Database requirements of SEBI

Daiichi Sankyo joins Startup Creasphere's Program Powered by Plug and Play

Handheld releases new Nautiz X81: An ultra-rugged 5G Android 12 handheld with a familiar feel

The Mindful Foundation brings courses from Oxford Mindfulness Foundation to India

UST Recognized for Human Resources Excellence Across Nine Categories at the 2022 Brandon Hall Awards

ScentAir Continues its Sustainability Initiatives to Enhance Immersive Sensory Experience

Sweden spellbinds travellers with new chilling audio story

Edvoy launches 'Refer a friend' programme as thank you to student advocates

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

WinWire Has Earned the Modernization of Web Applications to Microsoft Azure Advanced Specialization

UNIVERSAL MUSIC INDIA ACQUIRES MAJORITY STAKE IN TM VENTURES, A LEADING INDIAN MUSIC & ENTERTAINMENT COMPANY

M&M'S® Welcomes First New Character in a Decade

Global Business Leaders Say Hybrid Cloud is Critical to Modernization, Yet Security, Skills and Compliance Concerns Impede Success

GLOBAL STANDARD OF CARE SIGNIFICANTLY REDUCED DUE TO MENTAL HEALTH OF HEALTHCARE WORKERS

Vieworks to Showcase Industrial Cameras and Lenses at VISION 2022

Eviation's Alice Achieves Milestone with First Flight of All-Electric Aircraft

SAUDI ARABIA IS THE FASTEST GROWING TOURISM DESTINATION IN THE G20

Internet sensation Khaby Lame announced as QNB Group's Official FIFA World Cup Qatar 2022™ Brand Ambassador

GIGABYTE Launches Z790 Series Motherboards Supporting Dual-Generation Intel Processors

Deltek Research to Unveil Top Federal Contracting Opportunities for 2023

ViewSonic Unveils Industry-First Foldable 135" All-in-One LED Display Solution Kit

NEOM Tech & Digital Company steps into the future as 'Tonomus'

Global Fab Equipment Spending Forecast to Reach All-Time High of Nearly $100 Billion in 2022, SEMI Reports

Kohler India celebrates their 10th Year of Pecha Kucha in New Delhi, India

U.S. Soy Sustainability Assurance Protocol (SSAP) Certificates Can Now Be Transferred

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

Old Mission Selects Solace to Support Rapid Growth of Business through Event-Driven Architecture

GIGABYTE Launches Four AMD X670 Motherboards for New Ryzen 7000 Processors

SRK Knowledge Foundation announces transformational partnership with The Global Network for Zero

LyondellBasell Announces Organizational Changes

HarperCollins India presents HAPPILY INSURED: Your Guide to Understanding Insurance and Leading a Stress-Free Life by Kapil Mehta

Hisense Unveils Its FIFA World Cup Qatar 2022™ TVC "Perfect Match" Ahead of Tournament

The 2022 4th "My China Story" International Short Video Competition Award Ceremony was held in Hangzhou, Zhejiang

Light up the festive season with 'Sale Dhamaka' on MSI's laptop range

GLOBAL LEADERS, EXPERTS, AND CULTURAL ICONS CONVENE AT THE MILKEN INSTITUTE ASIA SUMMIT TO CELEBRATE A TRANSFORMED WORLD

Bank of Baroda rolls out 'Khushiyon ka Tyohaar' as the Festive Season begins

XCMG New Port Machinery's High-end Intelligent Industrial Development Project Base Launches Production

NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH CONDUCTS A GLOBAL ANNUAL MEETING TO ADDRESS RESEARCH IN SURGERY IN INDIA

DEAKIN UNIVERSITY HUBS to be set up in India at OP Jindal Global University, Symbiosis International University and Chitkara University

TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to Turkey

Top 50 Start-ups Bringing Innovation to the Global Homes and Buildings Industry

How Healthcare Organizations Can Enhance a Holistic Patient and Member View by Improving Insights from Data

Tata AIA Life Fortune Guarantee Pension gets a powerful upgrade

PDRL aims to certify 10,000+ candidates on AeroMegh Platform in the Drone Industry by the year 2024

DAZN ACCELERATES GLOBAL GROWTH MOMENTUM WITH ACQUISITION OF ELEVEN GROUP BUSINESSES

GoingZero Big Diwali Sale: Up to 40% Discount And Free Shipping On Zero Waste Products

Slow-fashion brand FREECULTR becomes the official merchandise partner for FIFA 2022™

Purple Quarter Facilitates HCAH's CTO, Ex-DealShare Techie Onboarded

Ghodawat Consumer awarded - Fastest growing FMCG Company of 2022

Cine Star Cricket League launched with television and entertainment industry's Divas

ELLE FANNING IS THE AMBASSADOR OF FAME, PACO RABANNE'S NEW FEMININE FRAGRANCE

Saudi Data, AI Authority (SDAIA) and Ministry of Energy Partner with IBM to Accelerate Sustainability Initiatives in Saudi Arabia Using AI

Unstoppable Women of Web3 Launches New Education Streams

PNAS Partners with Straive for Production Services

MOBILEUM convenes the region's leading telecom operators at WEMEET ASIA 2022

Bizverse has officially become a Meta long-term strategic partnership

STL divests IDS as a part of its ongoing portfolio realignment

Frost & Sullivan Honors Tampa Electric Company and Warren, Simpson & Butler County Water Districts with Itron Excellence in Resourcefulness Awards

Mindray Showcases Hematology Innovations and Academic Achievements to the World at ISLH 2022

Deepak Chopra & Seva.Love Announce "ChopraVerse: House of Enlightenment," the Metaverse for Wellbeing in Collaboration with Utopia

MSC TO DEVELOP AIR CARGO SOLUTION IN RESPONSE TO MARKET DEMAND

Harpercollins is proud to announce the upcoming release of The Anarchist Cookbook: A Toolkit to Protest and Peaceful Resistance by Aakar Patel Illustrations by PenPencilDraw

Saudi Arabia launches Nusuk, an integrated digital platform, to facilitate pilgrim journeys for visitors from around the world

MEIL's wholly owned subsidiary MeghaGas, now MCGDPL, to execute City Gas Distribution

Yabx emerges as a leader in digital lending platforms at the top Global Fintech Awards

FII Institute reveals the world's top priority is the rising cost of living

All about IBSAT - One of the Top MBA Entrance Exams in India

MAPIC India 2022 honors India's most admired retail and tech innovators at the MAPIC India Retail Awards

Hasiru Dala Innovations joins forces with Satma CE to give immutable waste traceability from collection to final product made from waste

Bank of Baroda launches Baroda Tiranga Deposits

Alicon Castalloy Limited wins large, multi-year order from Jaguar Land Rover for eMobility Platform

mCaffeine's Biggest Body Care Launch Gets an Overwhelming Response from the Audience: 1 Consumer Subscribed Every 3 Seconds for the Launch

On World Lung Day, Alkem Laboratories pledge to spread awareness about lung diseases through its initiative 'The Healthy Lungs'

LONGi is to showcase its award-winning Hi-MO 5 Series at the Renewable Energy India Expo 2022, unveiling its new Hydrogen Business exclusively for Indian customers

LEXUS INDIA ANNOUNCES MENTORS FOR THE LEXUS DESIGN AWARD INDIA 2023

Mane Kancor CEO Geemon Korah hailed as one of the best CEO's in India

SVKM's NMIMS signs an MoU with HTWG Konstanz, Germany, for short study and research

Top HR Chiefs from TTK Prestige, Silicon Labs, Virtusa, Bureau Veritas at Woxsen's Global HR Leadership Conclave 2022

Mastercard expands decades-long football legacy through GUINNESS WORLD RECORDS™ title with Luis Figo

Soroco and Whatfix Announce Strategic Partnership

ElevenEs produces a prototype of the largest LFP battery cell in Europe

SHEIN CELEBRATED "ROCK THE RUNWAY: SHEIN FOR ALL", ITS FW22 FASHION SHOW

Huawei Hosts the 9th Global Rail Summit in Berlin

Campus With A Conscience hosts a-week long SDG festival

Woxsen University spearheading the internationalisation of higher education in the region through brand new initiatives

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Uttarakhand CM congratulates Lt Gen Anil...
WBSSC scam: Partha, Arpita's judicial cu...
Sacrosanct duty of husband to maintain w...
Prohibition raid leaves Bihar police sta...
Mumbai: Lata Mangeshkar music college la...
Defence Minister visits frontline areas ...
More...    
 
 Top Stories
Navratri 2022: Morning arti perform... 
"We strive for a relationship with ... 
EAM Jaishankar assures US administr... 
J-K: 2 injured after blast in parke... 
Arrest warrant issued against produ... 
Delhi HC dismisses plea of Facebook... 
Afghan women face social, economic ... 
Delhi Police arrests shooters of Go...